Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Refractory Prostate Cancer Disease”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT05689021
What this trial is testing

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
Mayo Clinic 8
Testing effectiveness (Phase 2)Study completedNCT00025116
What this trial is testing

ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Who this might be right for
Prostate Cancer
NCIC Clinical Trials Group 40
Testing effectiveness (Phase 2)Study completedNCT00976755
What this trial is testing

Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer

Who this might be right for
Prostate Cancer
Swiss Cancer Institute 37
Large-scale testing (Phase 3)Study completedNCT01578655
What this trial is testing

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Who this might be right for
Prostate Cancer
Achieve Life Sciences 630
Testing effectiveness (Phase 2)Study completedNCT01083368
What this trial is testing

Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy

Who this might be right for
Prostate Cancer
Case Comprehensive Cancer Center 22
Testing effectiveness (Phase 2)Study completedNCT00498797
What this trial is testing

E3-Hormone Refractory Prostrate Cancer Taxotere Combination

Who this might be right for
Prostate CancerMetastaticHormone Refractory
Sanofi 86
Early research (Phase 1)Study completedNCT03218826
What this trial is testing

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

Who this might be right for
Advanced Breast CarcinomaAdvanced Malignant Solid NeoplasmAdvanced Prostate Carcinoma+23 more
National Cancer Institute (NCI) 23
Testing effectiveness (Phase 2)Study completedNCT01284920
What this trial is testing

MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients

Who this might be right for
Prostate CancerProstate NeoplasmsCastration Resistant Prostate Cancer (CRPC)
Astellas Pharma Inc 47
Testing effectiveness (Phase 2)Looking for participantsNCT05413850
What this trial is testing

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Who this might be right for
Prostate CancerMetastatic Castration-resistant Prostate CancermCRPC+3 more
Blue Earth Therapeutics Ltd 82
Large-scale testing (Phase 3)Active Not RecruitingNCT01946204
What this trial is testing

Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Aragon Pharmaceuticals, Inc. 1,207
Testing effectiveness (Phase 2)Study completedNCT03456804
What this trial is testing

ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMetastatic Prostate Carcinoma+2 more
Barbara Ann Karmanos Cancer Institute 13
Testing effectiveness (Phase 2)Study completedNCT00039104
What this trial is testing

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

Who this might be right for
Adenocarcinoma of the ProstateRecurrent Prostate CancerStage IV Prostate Cancer
National Cancer Institute (NCI) 50
Testing effectiveness (Phase 2)Study completedNCT02077634
What this trial is testing

Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)

Who this might be right for
Prostate Cancer
Universität des Saarlandes 68
Large-scale testing (Phase 3)Study completedNCT01695135
What this trial is testing

Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy

Who this might be right for
Prostate Neoplasms
Janssen Research & Development, LLC 214
Testing effectiveness (Phase 2)Looking for participantsNCT06922318
What this trial is testing

The COSMYC Trial (COmbined Suppression of MYC)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 50
Early research (Phase 1)Study completedNCT00916123
What this trial is testing

Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Weill Medical College of Cornell University 15
Testing effectiveness (Phase 2)Study completedNCT00040586
What this trial is testing

Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2

Who this might be right for
Prostatic Neoplasms
BZL Biologics
Not applicableApproved For MarketingNCT01217697
What this trial is testing

Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Who this might be right for
Prostate NeoplasmsGenital Neoplasms, MaleUrogenital Neoplasms+1 more
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Testing effectiveness (Phase 2)WithdrawnNCT01658527
What this trial is testing

TAK-700 in Castration Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Testing effectiveness (Phase 2)WithdrawnNCT02906605
What this trial is testing

The Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Janssen Research & Development, LLC
Next Page